Skip to main content

Stryker Corporation stock price and financials

  • SYK · NYSE
  • Medical devices
  • Health Care Equipment
  • S&P 500
$309.64−0.88%Close 13 Nov 2026
EV / EBITDA
18.45
Beta · 1 year
0.24
Return · 1 year
−15.7%
52-week range$267.00 — $389.33

Share price close 16 Nov 2026

+6.3%1 monthHigh $339.65Low $291.86
$280$300$320$340Q3 FY2026 report filed 30 Oct 202623 Oct29 Oct4 Nov10 Nov16 Nov
+1.6%6 monthsHigh $352.25Low $269.75
$250$275$300$325$350$375Q2 FY2026 report filed 31 Jul 2026Q3 FY2026 report filed 30 Oct 20264 Jun2 Jul30 Jul26 Aug23 Sep20 Oct16 Nov
−11.3%year to dateHigh $387.46Low $269.75
$250$300$350$400Q4 FY2025 report filed 11 Feb 2026Q1 FY2026 report filed 11 May 2026Q2 FY2026 report filed 31 Jul 2026Q3 FY2026 report filed 30 Oct 202611 Feb30 Mar14 May1 Jul17 Aug1 Oct16 Nov
−14.0%1 yearHigh $387.46Low $269.75
$250$300$350$400Q4 FY2025 report filed 11 Feb 2026Q1 FY2026 report filed 11 May 2026Q2 FY2026 report filed 31 Jul 2026Q3 FY2026 report filed 30 Oct 2026Jan 26Mar 26Apr 26Jun 26Aug 26Sep 26Nov 26
+9.9%3 yearsHigh $403.53Low $269.75
$250$300$350$400$450Q4 FY2023 report filed 14 Feb 2024Q1 FY2024 report filed 1 May 2024Q2 FY2024 report filed 31 Jul 2024Q3 FY2024 report filed 30 Oct 2024Q4 FY2024 report filed 12 Feb 2025Q1 FY2025 report filed 2 May 2025Q2 FY2025 report filed 1 Aug 2025Q3 FY2025 report filed 31 Oct 2025Q4 FY2025 report filed 11 Feb 2026Q1 FY2026 report filed 11 May 2026Q2 FY2026 report filed 31 Jul 2026Q3 FY2026 report filed 30 Oct 2026Apr 24Sep 24Feb 25Aug 25Jan 26Jun 26Nov 26
+180%10 yearsHigh $403.53Low $112.08
$100$200$300$400$500Apr 18Sep 19Feb 21Jul 22Jan 24Jun 25Nov 26

Quarterly or annual report filed

In one paragraph

Stryker Corporation reported revenue of $25.1 billion for fiscal year 2025 (the twelve months to 31 Dec 2025), up 11.2% from fiscal 2024. Net income was $3.25 billion and diluted earnings per share $8.40.

In its latest reported quarter, the third quarter of fiscal 2026 (the three months to 30 Sep 2026), revenue was $6.52 billion, up 7.6% from a year earlier.

Figures from Stryker Corporation's annual and quarterly reports, compiled and checked by AapWire. Latest report filed 30 Oct 2026.

Revenue FY2025
$25.12B+11.2%
Net income
$3.25B+8.5%
Diluted EPS
$8.40+8.2%
Gross margin
64.0%+0.1 pts
Free cash flow
$4.28B+22.8%
Net debt
$12.35B+27.1%

Fiscal 2025 against fiscal 2024; bars show the last 10 fiscal years; net debt is borrowings and operating lease liabilities less cash and short-term investments at the year end.

Revenue and net income fiscal 2016–2025

  • Revenue
  • Net income
$0$10B$20B$30BRevenue, FY16: $11.32BNet income, FY16: $1.65BFY16Revenue, FY17: $12.44BNet income, FY17: $1.02BFY17Revenue, FY18: $13.6BNet income, FY18: $3.55BFY18Revenue, FY19: $14.88BNet income, FY19: $2.08BFY19Revenue, FY20: $14.35BNet income, FY20: $1.6BFY20Revenue, FY21: $17.11BNet income, FY21: $1.99BFY21Revenue, FY22: $18.45BNet income, FY22: $2.36BFY22Revenue, FY23: $20.5BNet income, FY23: $3.17BFY23Revenue, FY24: $22.59BNet income, FY24: $2.99BFY24Revenue, FY25: $25.12BNet income, FY25: $3.25BFY25

Latest quarter · Q3 FY2026 to 30 Sep 2026, filed 30 Oct 2026 · Full results →

Revenue
$6.52B+7.6% on a year
Gross margin
65.2%+1.6 pts on a year
Operating income
$1.03B−8.9% on a year
Net income
$753.0M−12.3% on a year
Diluted EPS
$1.96−11.7% on a year
Free cash flow
$1.22B−9.5% on a year

Comparable companies All of Health Care →

Stryker Corporation beside the other S&P 500 members in Health Care Equipment, by market value.

Stryker Corporation and comparable companies
CompanyMarket valueDay1 yearRevenue growthNet marginP/E
Stryker CorporationSYK—−0.9%−15.7%———
Abbott LaboratoriesABT$188.1B+1.2%−15.8%+10.0%9.7%40.0
Intuitive SurgicalISRG$152.6B+0.8%−22.5%+20.5%25.5%51.6
Boston ScientificBSX$63.86B+0.3%−57.4%+8.9%16.6%18.2
Edwards LifesciencesEW$61.47B+1.3%+25.2%+13.4%15.3%60.2
Becton DickinsonBDX$59.14B+1.1%+44.4%−2.6%4.5%62.9
Idexx LaboratoriesIDXX$55.78B+0.9%−1.3%+11.9%25.4%47.2

Market value and moves at the latest close. Revenue growth compares the last twelve months with the twelve before; net margin and P/E over the last twelve months; P/E is left blank where earnings are negative.

Margins fiscal 2016–2025

  • Gross
  • Operating
  • Net
0%25%50%75%64.0%19.5%12.9%FY16FY19FY22FY25

Stryker Corporation revenue by segment, product and region

Fiscal years, as the company cuts its revenue in its annual reports; the change on a year under each figure. A change is left out from a loss, from a sliver of revenue, or across a change in how the company reports.

By segment

Stryker Corporation revenue by segment, by fiscal year
RevenueFY 2021FY 2022FY 2023*FY 2024FY 2025
MedSurg and Neurotechnology:$9.54B$10.89B+14.2%$10.56B$11.75B+11.3%$13.69B+16.5%
Orthopaedics:$7.57B$7.56B−0.2%$9.94B$10.84B+9.1%$11.42B+5.4%
Total revenue$17.11B$18.45B$20.50B$22.59B$25.12B

* The company changed how it cuts its revenue from this year; the lines before and after are not compared.

By region

Stryker Corporation revenue by region, by fiscal year
RevenueFY 2021FY 2022FY 2023FY 2024FY 2025
United States$12.32B$13.64B+10.7%$15.26B+11.9%$16.94B+11.1%$19.01B+12.2%
Europe, Middle East, Africa$2.30B$2.35B+2.1%$2.62B+11.5%$2.90B+10.7%$3.18B+9.8%
Asia Pacific$1.97B$1.89B−4.5%$1.95B+3.2%$2.02B+3.8%$2.16B+7.1%
Other foreign countries$515.0M$578.0M+12.2%$677.0M+17.1%$735.0M+8.6%$765.0M+4.1%
Total revenue$17.11B$18.45B$20.50B$22.59B$25.12B

Financial statements

Fiscal years, the latest ending 31 Dec 2025. Amounts in USD. On a narrow screen the table opens on the latest year and scrolls back.

Income statement

Stryker Corporation income statement, annual
PeriodFY 2016FY 2017FY 2018FY 2019FY 2020FY 2021FY 2022FY 2023FY 2024FY 2025
Revenue$11.32B$12.44B$13.60B$14.88B$14.35B$17.11B$18.45B$20.50B$22.59B$25.12B
Revenue growth+13.9%+9.9%+9.3%+9.4%−3.6%+19.2%+7.8%+11.1%+10.2%+11.2%
Gross profit$7.50B$8.18B$8.94B$9.70B$9.06B$10.97B$11.58B$13.06B$14.44B$16.07B
Operating income$2.17B$2.30B$2.54B$2.71B$2.22B$2.58B$2.84B$3.89B$3.69B$4.89B
Net income$1.65B$1.02B$3.55B$2.08B$1.60B$1.99B$2.36B$3.17B$2.99B$3.25B
Diluted EPS$4.35$2.68$9.34$5.48$4.20$5.21$6.17$8.25$7.76$8.40
Gross margin66.3%65.7%65.7%65.1%63.1%64.1%62.8%63.7%63.9%64.0%
Operating margin19.2%18.5%18.7%18.2%15.5%15.1%15.4%19.0%16.3%19.5%
Net margin14.5%8.2%26.1%14.0%11.1%11.7%12.8%15.4%13.2%12.9%

Cash flow

Stryker Corporation cash flow, annual
PeriodFY 2016FY 2017FY 2018FY 2019FY 2020FY 2021FY 2022FY 2023FY 2024FY 2025
Operating cash flow$1.92B$1.56B$2.61B$2.19B$3.28B$3.26B$2.62B$3.71B$4.24B$5.04B
Capital expenditure$490.0M$598.0M$572.0M$649.0M$487.0M$525.0M$588.0M$575.0M$755.0M$761.0M
Free cash flow$1.43B$961.0M$2.04B$1.54B$2.79B$2.74B$2.04B$3.14B$3.49B$4.28B

Balance sheet and shares

Stryker Corporation balance sheet and shares, annual
PeriodFY 2016FY 2017FY 2018FY 2019FY 2020FY 2021FY 2022FY 2023FY 2024FY 2025
Cash and equivalents$3.32B$2.54B$3.62B$4.34B$2.94B$2.94B$1.84B$2.97B$3.65B$4.01B
Total debt$6.91B$7.22B$9.86B$11.48B$14.43B$12.90B$13.53B$13.49B$14.12B$16.36B
Shareholders' equity$9.55B$9.97B$11.73B$12.81B$13.08B$14.88B$16.62B$18.59B$20.63B$22.42B
Diluted shares379M380M380M380M380M382M382M384M386M387M
Dividends per share$1.56—————————

Quarterly figures

The last eight fiscal quarters, the latest ending 30 Sep 2026. Year-on-year growth compares the same quarter of the previous fiscal year.

Stryker Corporation quarterly financial figures
PeriodQ4 FY2024Q1 FY2025Q2 FY2025Q3 FY2025Q4 FY2025Q1 FY2026Q2 FY2026Q3 FY2026
Revenue$6.44B$5.87B$6.02B$6.06B$7.17B$6.02B$6.59B$6.52B
Revenue, year on year+10.7%+11.9%+11.1%+10.2%+11.4%+2.6%+9.4%+7.6%
Gross margin64.9%63.8%63.8%63.6%64.5%63.3%68.3%65.2%
Operating income$581.0M$837.0M$1.11B$1.14B$1.80B$936.0M$1.66B$1.03B
Net income$546.0M$654.0M$884.0M$859.0M$849.0M$745.0M$1.28B$753.0M
Diluted EPS$1.41$1.69$2.29$2.22$2.20$1.93$3.30$1.96
Free cash flow$1.67B$127.0M$928.0M$1.35B$1.88B$415.0M$1.06B$1.22B

Operating KPIs

The operating figures Stryker Corporation reports beside its statements, then its revenue by product, segment and region, latest period first. Each links to its full history.

Stryker Corporation operating KPIs
KPILatestPeriodChange on a yearRecent periods
Organic net sales (change on a year)7.7%quarter to 30 Sep 2026down 1.8 points
Neuro Cranial Instruments revenue$670.0Mquarter to 30 Sep 2026up 5.2%
Orthopaedic Instruments revenue$535.0Mquarter to 30 Sep 2026up 8.7%
Neuro Cranial - Interventional Spine revenue$129.0Mquarter to 30 Jun 2025up 31.6%
Enabling Technologies revenue$28.0Mquarter to 30 Sep 2026down 37.8%
Medical revenue$1.1Bquarter to 30 Sep 2026up 9.7%
Endoscopy revenue$1.0Bquarter to 30 Sep 2026up 14.0%
Trauma and Extremities revenue$1.0Bquarter to 30 Sep 2026up 5.2%
Instruments revenue$996.0Mquarter to 30 Sep 2026up 5.0%
Instruments (earlier basis) revenue$920.0Mquarter to 31 Mar 2026up 9.8%
Ortho Tech revenue$754.0Mquarter to 30 Sep 2026up 15.8%
Neuro Cranial revenue$669.0Mquarter to 31 Dec 2025up 10.9%
Knees revenue$635.0Mquarter to 30 Sep 2026up 1.1%
Vascular revenue$566.0Mquarter to 30 Sep 2026up 7.8%
Hips revenue$453.0Mquarter to 30 Sep 2026down 0.9%
Spinal Implants revenue$4.0Mquarter to 30 Sep 2026down 33.3%
MedSurg and Neurotechnology (revenue)$3.7Bquarter to 30 Sep 2026up 9.2%
Orthopaedics (revenue)$2.9Bquarter to 30 Sep 2026up 5.7%
United States revenue$5.0Bquarter to 30 Sep 2026up 8.3%
Europe, Middle East, Africa revenue$3.2Bfiscal year to 31 Dec 2025up 9.8%
Asia Pacific revenue$2.2Bfiscal year to 31 Dec 2025up 7.1%
International revenue$1.6Bquarter to 30 Sep 2026up 5.7%

Method

Each period is read from the report the company filed and checked against accounting identities before it is shown; a figure that does not pass is left blank rather than estimated. Free cash flow is operating cash flow less capital expenditure. Fiscal years follow the company's own calendar. See data and methodology.

The same figures as plain text and JSON.

Questions

What was Stryker Corporation's revenue in fiscal 2025?

$25.1 billion for fiscal year 2025 (the twelve months to 31 Dec 2025), as reported in its annual report.

What was Stryker Corporation's net income in fiscal 2025?

$3.25 billion for fiscal year 2025 (the twelve months to 31 Dec 2025).

What were Stryker Corporation's diluted earnings per share in fiscal 2025?

$8.40 for fiscal year 2025 (the twelve months to 31 Dec 2025).

What is Stryker Corporation's gross margin?

64.0% for fiscal year 2025 (the twelve months to 31 Dec 2025): gross profit divided by revenue.

What is Stryker Corporation's operating margin?

19.5% for fiscal year 2025 (the twelve months to 31 Dec 2025): operating income divided by revenue.

How much free cash flow did Stryker Corporation generate in fiscal 2025?

$4.28 billion for fiscal year 2025 (the twelve months to 31 Dec 2025): operating cash flow less capital expenditure.

Where does Stryker Corporation's revenue come from?

In fiscal 2025, by segment: MedSurg and Neurotechnology: $13.69B (55%), Orthopaedics: $11.42B (45%), out of $25.12B in all, as stated in its annual report.

In the terminal

Twenty years of Stryker Corporation's figures, KPIs, guidance and a cash-flow valuation.

  • Every report line and operating figure, quarter by quarter
  • Guidance against what was delivered
  • Insider trades and institutional holders
  • Alerts on results, filings and price
See plans